• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过对间变大细胞淋巴瘤的深度 RNA 测序鉴定到新型 TRAF1-ALK 融合。

Novel TRAF1-ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma.

机构信息

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

出版信息

Genes Chromosomes Cancer. 2013 Nov;52(11):1097-102. doi: 10.1002/gcc.22104. Epub 2013 Sep 2.

DOI:10.1002/gcc.22104
PMID:23999969
Abstract

Chromosomal translocations leading to expression of abnormal fusion proteins play a major role in the pathogenesis of various hematologic malignancies. The recent development of high-throughput, "deep" sequencing has allowed discovery of novel translocations leading to a rapid increase in understanding these diseases. Translocations involving the anaplastic lymphoma kinase (ALK) gene leading to ALK fusion proteins originally were discovered in anaplastic large cell lymphomas (ALCLs). Among ALCLs, NPM1-ALK fusions are most common and lead to nuclear localization of the fusion protein. Here, we present a 50-year-old male with ALCL demonstrating cytoplasmic ALK immunoreactivity only, suggesting the presence of a non-NPM1 fusion partner. We performed deep RNA sequencing of tumor tissue from this patient and identified a novel transcript fusing Exon 6 of TRAF1 to Exon 20 of ALK. The TRAF1-ALK fusion transcript was confirmed at the mRNA level by Sanger sequencing and the fusion protein was visualized by Western blot. The discovery of this TRAF1-ALK fusion expands the diversity of known ALK fusion partners and highlights the power of deep sequencing for fusion transcript discovery. © 2013 Wiley Periodicals, Inc.

摘要

导致异常融合蛋白表达的染色体易位在各种血液恶性肿瘤的发病机制中起主要作用。高通量、“深度”测序的最新发展允许发现导致对这些疾病的快速理解的新易位。涉及间变性淋巴瘤激酶(ALK)基因的易位导致 ALK 融合蛋白最初在间变性大细胞淋巴瘤(ALCL)中被发现。在 ALCL 中,NPM1-ALK 融合最常见,并导致融合蛋白的核定位。在这里,我们展示了一名 50 岁男性的 ALCL,仅表现出细胞质 ALK 免疫反应性,表明存在非 NPM1 融合伙伴。我们对来自该患者的肿瘤组织进行了深度 RNA 测序,并鉴定出一种新型转录物,将 TRAF1 的外显子 6 融合到 ALK 的外显子 20。通过 Sanger 测序在 mRNA 水平上证实了 TRAF1-ALK 融合转录本,并通过 Western blot 可视化融合蛋白。TRAF1-ALK 融合的发现扩展了已知 ALK 融合伙伴的多样性,并强调了深度测序在融合转录本发现中的强大功能。©2013 年 Wiley 期刊公司

相似文献

1
Novel TRAF1-ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma.通过对间变大细胞淋巴瘤的深度 RNA 测序鉴定到新型 TRAF1-ALK 融合。
Genes Chromosomes Cancer. 2013 Nov;52(11):1097-102. doi: 10.1002/gcc.22104. Epub 2013 Sep 2.
2
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.一种具有TRAF1-ALK间变性大细胞淋巴瘤易位的新型患者来源肿瘤移植模型。
Leukemia. 2015 Jun;29(6):1390-401. doi: 10.1038/leu.2014.347. Epub 2014 Dec 23.
3
Detection of a TRAF1-ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitor-resistant disease.在一名患有化疗和ALK抑制剂耐药性疾病的间变性大细胞淋巴瘤患者中检测到TRAF1-ALK融合。
BMC Res Notes. 2015 Jul 18;8:308. doi: 10.1186/s13104-015-1277-7.
4
Variant translocation partners of the anaplastic lymphoma kinase (ALK) gene in two cases of anaplastic large cell lymphoma, identified by inverse cDNA polymerase chain reaction.通过反向cDNA聚合酶链反应鉴定的两例间变性大细胞淋巴瘤中间变性淋巴瘤激酶(ALK)基因的变异易位伙伴。
J Clin Exp Hematop. 2014;54(3):225-35. doi: 10.3960/jslrt.54.225.
5
Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.TPM3-ALK阳性间变性大细胞淋巴瘤的基因表达谱分析揭示了与NPM-ALK阳性间变性大细胞淋巴瘤重叠和独特的模式。
Leuk Res. 2008 Mar;32(3):383-93. doi: 10.1016/j.leukres.2007.07.012. Epub 2007 Aug 27.
6
Molecular Screening in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: Anaplastic Lymphoma Kinase Analysis, Next-Generation Sequencing Fusion Gene Detection, and T-Cell Receptor Immunoprofiling.间变性大细胞淋巴瘤中间变性淋巴瘤激酶阳性的分子筛选:间变性淋巴瘤激酶分析、下一代测序融合基因检测和 T 细胞受体免疫组化分析。
Mod Pathol. 2024 Mar;37(3):100428. doi: 10.1016/j.modpat.2024.100428. Epub 2024 Jan 23.
7
Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.具有 RNF213-、ATIC- 和 TPM3-ALK 融合变异的间变性大细胞淋巴瘤伴间变性淋巴瘤激酶阳性,其特征是重排的 ALK 基因拷贝数增加。
Haematologica. 2017 Sep;102(9):1605-1616. doi: 10.3324/haematol.2016.146571. Epub 2017 Jun 28.
8
Diagnostic Capability of Next-Generation Sequencing Fusion Analysis in Identifying a Rare CASE of Associated Anaplastic Large Cell Lymphoma.下一代测序融合分析在诊断罕见的伴间变性大细胞淋巴瘤病例中的诊断能力
Front Oncol. 2020 May 8;10:730. doi: 10.3389/fonc.2020.00730. eCollection 2020.
9
Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.在间变性大细胞淋巴瘤和炎性肌纤维母细胞瘤中鉴定间变性淋巴瘤激酶(ALK)的新型融合伴侣。
Genes Chromosomes Cancer. 2002 Aug;34(4):354-62. doi: 10.1002/gcc.10033.
10
Detection of TRAF1-ALK fusion in skin lesions of systemic ALK+ anaplastic large cell lymphoma initially involving the skin and the draining lymph node.检测系统性 ALK+间变大细胞淋巴瘤初发皮肤及引流淋巴结损害中 TRAF1-ALK 融合。
J Dermatol. 2024 Jan;51(1):120-124. doi: 10.1111/1346-8138.16981. Epub 2023 Sep 27.

引用本文的文献

1
Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines.肿瘤衍生抗原肽作为潜在的癌症疫苗。
Int J Mol Sci. 2024 Apr 30;25(9):4934. doi: 10.3390/ijms25094934.
2
Updates in pathobiological aspects of anaplastic large cell lymphoma.间变性大细胞淋巴瘤病理生物学方面的进展
Front Oncol. 2023 Sep 22;13:1241532. doi: 10.3389/fonc.2023.1241532. eCollection 2023.
3
How molecular advances may improve the diagnosis and management of PTCL patients.分子学进展如何改善外周T细胞淋巴瘤(PTCL)患者的诊断与管理。
Front Oncol. 2023 Jun 23;13:1202964. doi: 10.3389/fonc.2023.1202964. eCollection 2023.
4
Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment.间变性大细胞淋巴瘤:分子发病机制与治疗
Cancers (Basel). 2022 Mar 24;14(7):1650. doi: 10.3390/cancers14071650.
5
Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma.ALK阳性间变性大细胞淋巴瘤中ALK酪氨酸激酶抑制剂耐药的整体观点。
Front Oncol. 2022 Feb 8;12:815654. doi: 10.3389/fonc.2022.815654. eCollection 2022.
6
RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-κB and MAPK signaling pathways.RNA 去甲基酶 ALKBH5 通过 TRAF1 介导的 NF-κB 和 MAPK 信号通路激活促进多发性骨髓瘤的发生。
Oncogene. 2022 Jan;41(3):400-413. doi: 10.1038/s41388-021-02095-8. Epub 2021 Nov 10.
7
Aberrant expression and genetic alteration of c-MYC in anaplastic large cell lymphoma.间变大细胞淋巴瘤中 c-MYC 的异常表达和遗传改变。
J Cancer Res Clin Oncol. 2022 Jan;148(1):267-278. doi: 10.1007/s00432-021-03691-7. Epub 2021 Jun 16.
8
Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas.复发/难治性外周 T 细胞淋巴瘤的分子靶向治疗。
Semin Hematol. 2021 Apr;58(2):78-84. doi: 10.1053/j.seminhematol.2021.02.004. Epub 2021 Mar 3.
9
Diagnostic Capability of Next-Generation Sequencing Fusion Analysis in Identifying a Rare CASE of Associated Anaplastic Large Cell Lymphoma.下一代测序融合分析在诊断罕见的伴间变性大细胞淋巴瘤病例中的诊断能力
Front Oncol. 2020 May 8;10:730. doi: 10.3389/fonc.2020.00730. eCollection 2020.
10
Advances in targeted therapy for malignant lymphoma.恶性淋巴瘤靶向治疗的进展。
Signal Transduct Target Ther. 2020 Mar 6;5(1):15. doi: 10.1038/s41392-020-0113-2.